Melody® transcatheter pulmonary valve implantation: Results from a French registry  by Fraisse, Alain et al.
Archives of Cardiovascular Disease (2014) 107, 607—614
Available  online  at
ScienceDirect
www.sciencedirect.com
CLINICAL RESEARCH
Melody® transcatheter  pulmonary  valve
implantation:  Results  from  a  French  registry
Implantation  de  la  valve  Melody® par  cathétérisme
interventionnel  :  résultats  du  registre  franc¸ais
Alain  Fraissea,  Philippe  Aldeberta,
Sophie  Malekzadeh-Milanib,c,  Jean-Benoit  Thambod,
Jean-Franc¸ois  Piéchaude,  Pascaline  Aucoururier f,
Gilles  Chatelier f,  Damien  Bonnetb,g,  Laurence  Iserinc,
Béatrice  Bonelloa,  Anass  Assaidi a,  Issam  Kammachea,
Younes  Boudjemlineb,c,g,∗
a Cardiologie  Pédiatrique,  hôpital  de  la  Timone-Enfants,  13385  Marseille,  France
b Pediatric  Cardiology,  unité  médico-chirurgicale  de  cardiologie  congénitale  et  pédiatrique,
centre de  référence  malformations  cardiaques  congénitales  complexes—M3C,  Necker  Hospital
for Sick  Children,  Assistance  publique  des  Hôpitaux  de  Paris,  149,  rue  de  Sèvres,  75015  Paris
cedex, France
c Unit  for  adults  with  congenital  heart  defects,  centre  de  référence  malformations
cardiaques  congénitales  complexes—M3C,  George-Pompidou  European  Hospital,  Assistance
publique des  Hôpitaux  de  Paris,  75015  Paris,  France
d Unit  for  children  and  adults  with  congenital  heart  defects,  hospital  Bordeaux,  33604
Bordeaux,  France
e Institut  hospitalier  Jacques-Cartier,  91300  Massy,  France
f Unit  of  Clinical  Research  (URC),  George-Pompidou  European  Hospital,  Assistance  publique
des Hôpitaux  de  Paris,  75015  Paris,  France
g Université  Paris-Descartes,  Sorbonne  Paris-Cité,  75008  Paris,  FranceReceived  2  July  2014;  received  in  revised  form  3  October  2014;  accepted  3  October  2014
Available online  6  November  2014
Abbreviations: MRI, magnetic resonance imaging; RVOT, right ventricular outﬂow tract; TPVI, transcatheter pulmonary valve implanta-
tion.
∗ Corresponding author. Pediatric Cardiology, unité médico-chirurgicale de cardiologie congénitale et pédiatrique, centre de référence
malformations cardiaques congénitales complexes—M3C, Necker Hospital for Sick Children, Assistance publique des Hôpitaux de Paris, 149,
rue de Sèvres, 75015 Paris cedex, France.
E-mail address: younes.boudjemline@nck.aphp.fr (Y. Boudjemline).
http://dx.doi.org/10.1016/j.acvd.2014.10.001
1875-2136/© 2014 Elsevier Masson SAS. All rights reserved.
608  A.  Fraisse  et  al.
KEYWORDS
Transcatheter;
Pulmonary  valve
implantation;
Cardiac
catheterization
Summary
Background.  —  Percutaneous  implantation  of  pulmonary  valves  has  recently  been  introduced
into clinical  practice.
Aim.  —  To  analyse  data  of  patients  treated  in  France  between  April  2008  and  December  2010.
Methods.  —  Prospective,  observational,  multi-centric  survey  by  means  of  a  database  registry  of
the Filiale  de  cardiologie  pédiatrique  et  congénitale.
Results.  —  Sixty-four  patients  were  included,  with  a  median  (range)  age  of  21.4  (10.5—77.3)
years. The  majority  (60.9%)  of  the  patients  were  New  York  Heart  Association  (NYHA)  class
II. The  most  common  congenital  heart  disease  was  tetralogy  of  Fallot  with  or  without  pul-
monary atresia  (50%).  Indication  for  valve  implantation  was  stenosis  in  21.9%,  regurgitation
in 10.9%  and  association  of  stenosis  and  regurgitation  in  67.2%.  Implantation  was  successful
in all  patients.  Pre-stenting  was  performed  in  96.9%  of  cases.  Median  (range)  procedure  time
was 92.5  (25—250)  minutes.  No  signiﬁcant  regurgitation  was  recorded  after  the  procedure,  and
the trans-pulmonary  gradient  was  signiﬁcantly  reduced.  Early  minor  complications  occurred  in
ﬁve cases  (7.8%).  Three  patients  died  during  a  median  follow-up  of  4.6  (0.2—5.2)  years,  two
from infectious  endocarditis  and  one  from  end-stage  cardiac  failure.  Surgical  reintervention
was required  in  three  patients.  Follow-up  with  magnetic  resonance  imaging  demonstrated  sig-
niﬁcant improvements  in  right  ventricular  volumes  and  pulmonary  regurgitation  in  mixed  and
regurgitant  lesions.
Conclusions.  —  Transcatheter  pulmonary  valve  implantation  is  highly  feasible  and  mid-term
follow-up  demonstrates  sustained  improvement  of  right  ventricular  function.  Late  endocarditis
is of  concern,  therefore  longer  follow-up  in  more  patients  is  urgently  needed  to  better  assess
long-term outcome.
Clinical  trial  registration.  —  NCT01250327.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
MOTS  CLÉS
Trans-cathéter  ;
Cathétérisme
interventionnel  ;
Implantation  de  valve
pulmonaire
Résumé
Contexte.  — La  valvulation  pulmonaire  percutanée  a  récemment  été  introduite  en  pratique
clinique.
Buts. —  Analyser  les  données  des  patients  traités  en  France  entre  avril  2008  et  décembre  2010.
Méthodes.  —  Étude  prospective,  observationnelle,  multicentrique  sous  la  forme  d’un  registre
sous l’égide  de  la  ﬁliale  de  cardiologie  pédiatrique  et  congénitale  de  la  Société  franc¸aise  de
cardiologie.
Résultats.  —  Soixante-quatre  patients  ont  été  inclus  à  un  âge  médian  de  21,4  (10,5—77,3)  ans.
La majorité  (60,9  %)  était  en  classe  New  York  Heart  Association  (NYHA)  II.  La  cardiopathie
congénitale  la  plus  fréquente  était  la  tétralogie  de  Fallot  avec  ou  sans  atrésie  pulmonaire  (50  %).
L’indication  de  valvulation  était  une  sténose  pure  chez  21,9  %,  une  régurgitation  chez  (10,9  %)  et
l’association  d’une  sténose  et  d’une  régurgitation  chez  67,2  %.  La  valvulation  a  été  réalisée  avec
succès chez  tous  les  patients.  Un  préstenting  a  été  fait  chez  96,9  %  des  cas.  La  durée  moyenne
(intervalle)  de  la  procédure  était  de  92,5  (25—250)  minutes.  Il  n’y  avait  pas  de  régurgitation
signiﬁcative  après  la  procédure,  et  le  gradient  transpulmonaire  a  été  signiﬁcativement  réduit.
Des complications  mineures  sont  survenues  dans  cinq  cas  (7,8  %).  Trois  patients  sont  décédés
durant le  suivi  median  de  4,6  (0,2—5,2)  ans,  deux  d’une  endocardite  infectieuse  et  un  d’une
insufﬁsance cardiaque  terminale.  Des  réinterventions  chirurgicales  ont  été  pratiquées  chez  trois
patients.  Le  suivi  par  l’imagerie  à  résonnance  magnétique  nucléaire  a  montré  une  amélioration
signiﬁcative  des  volumes  ventriculaires  droits  et  de  la  régurgitation  pulmonaire  dans  les  lésions
mixtes et  régurgitantes.
Conclusions.  —  La  valvulation  pulmonaire  par  cathétérisme  interventionnel  est  faisable.  Le  suivi
à moyen  terme  montre  une  amélioration  signiﬁcative  de  la  fonction  ventriculaire  droite.  Les
endocardites  tardives  sont  une  préoccupation  importante.  Des  études  avec  un  suivi  plus  long
et un  plus  grand  nombre  de  patient  sont  indispensables  aﬁn  de  mieux  évaluer  le  devenir  à  long
terme.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Background
Right  ventricular  outﬂow  tract  (RVOT)  dysfunction  after
repair  of  congenital  and  structural  heart  disease  has  been
treated,  during  the  past  four  decades,  by  surgical  placement
of  a  conduit  between  the  right  ventricle  and  the  pulmonary
artery  [1].  Due  to  patient  growth  and  conduit  degenera-
tion,  these  conduits  have  to  be  replaced  frequently  over  the
course  of  a  lifetime  [2—4].  Transcatheter  approaches  for  the
management  of  dysfunctional  RVOT  have  evolved  over  time,
from  high-pressure  balloon  dilation  [5]  and  stent  implan-
tation  [6]  to  transcatheter  pulmonary  valve  implantation
(TPVI)  [7,8].  Since  the  introduction  of  TPVI,  the  majority  of
studies  have  reported  its  feasibility  with  excellent  results
[9—13].
Our  study  reports  on  a  national  multicentre  registry
supported  by  the  Filiale  de  cardiologie  pédiatrique  et  con-
génitale  (FCPC)  and  funded  by  the  Ministery  oh  Health
(Soutien  aux  Techniques  Innovantes  et  Coûteuses,  2008).
Methods
Selection criteria and study design
From  May  2008  to  December  2010,  a  prospective,  observa-
tional,  multicentre  registry  was  used  to  assess  indications,
results  and  complications  of  TPVI  with  the  Melody® valve
(Medtronic  Inc.,  Minneapolis,  MN,  USA)  in  patients  with  dys-
functional  RVOT  conduits.  A  grant  was  offered  by  the  French
Ministry  of  Health  under  the  protocol  ‘‘Soutien  aux  Tech-
niques  Innovantes  et  Coûteuses  2008’’  to  study  TPVI  with
the  Melody® valve  in  64  patients.
Patients  with  obstruction,  pulmonary  regurgitation  or
mixed  lesions  were  included.  RVOT  procedures  included  bal-
loon  dilatation  with  or  without  bare  metal  stent  insertion
and  TPVI.  Patients  were  enrolled  in  ﬁve  tertiary  academic
centres  in  France  (Necker  Hospital  for  Sick  Children,  Paris;
George-Pompidou  European  Hospital,  Paris;  Institut  Hospi-
talier  Jacques-Cartier,  Massy;  Unit  for  children  and  adults
with  congenital  heart  defects,  Bordeaux  and  La  Timone  Hos-
pital,  Marseille).  Patients  were  included  according  to  each
implanting  centres’  indications  and  practice,  based  on  the
usual  criteria  used  for  surgical  or  TPVI:
• symptomatic  patients  with  Doppler  mean  gradi-
ent  >  35  mmHg  and/or  at  least  moderate  pulmonary
regurgitation;
• asymptomatic  patients  with  the  following  criteria  by:
magnetic  resonance  imaging  (MRI)  (right  ventricular  end-
diastolic  volume  index  >  150  mL/m2 or  Z-score  >  4;  right
ventricular  end-systolic  volume  index  >  80  mL/m2; right
ventricular  ejection  fraction  <  47%;  left  ventricular  ejec-
tion  fraction  <  55%;  large  RVOT  aneurysm)  and/or  electro-
cardiography  (sustained  tachyarrhythmia  related  to  right
heart  volume  load  with  QRS  duration  >  140  ms)  and/or
echocardiography  (mean  Doppler  gradient  >  40  mmHg)
and/or  haemodynamics  (RVOT  obstruction  with  RV  systolic
pressure  ≥  2/3  systemic  pressure).
Procedural  and  follow-up  data  were  entered  in  to
a  database  approved  by  an  institutional  review  board.
Demographic  data,  procedural  details  and  immediate  and
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id-term  outcomes  and  complications  were  obtained  for
ll  patients.  Patients  with  native  RVOT,  native  pulmonary
alve  stenosis  and  age  <  5  years  and/or  weight  <  25  kg
ere  excluded.  Patients  with  active  endocarditis,  infec-
ion  or  sepsis,  pregnancy  or  central  vein  occlusion  were
lso  excluded.  During  pre-implantation  catheterization,
atients  in  whom  a  coronary  compression  was  diagnosed
ere  also  excluded.  The  survey  was  approved  by  the
ational  ethics  committee.  Written  informed  consent  was
btained  from  each  patient  and/or  his/her  parents  or  legal
uardian.  The  study  is  registered  at  the  National  Institute  of
ealth  website  (http://www.clinicaltrials.gov)  with  identi-
er  NCT01250327.
re-procedure evaluation
ll  patients  underwent  a pre-procedure  clinical  evalua-
ion  including  electrocardiogram  (ECG),  echocardiography
assessment  of  biventricular  function,  pulmonary  regurgita-
ion  and  right  ventricular  pressure),  chest  X-ray,  exercise
esting,  MRI  (assessment  of  ventricular  volumes  by  man-
ally  tracing  the  epicardial  and  endocardial  borders  and
valuation  of  ejection  fraction  and  pulmonary  regurgitation
raction).
iagnostic catheterization
ardiac  catheterization  was  performed  under  sedation  or
eneral  anaesthesia.  RVOT  stenosis  was  deemed  as  the
rimary  indication  if  the  RVOT  peak-to-peak  gradient  and
V  pressure  were  >  25  mmHg  and  >  2/3  systemic  pressure,
espectively.  Pulmonary  regurgitation  was  deemed  to  be  the
rimary  indication  in  the  presence  of  angiographically  sig-
iﬁcant  pulmonary  regurgitation  with  an  RVOT  peak  systolic
ressure  ≤  25  mmHg.  Patients  who  did  not  meet  the  speciﬁc
riteria  for  RVOT  stenosis  or  regurgitation  were  classiﬁed  as
ixed  lesions.
rocedure
he  Medtronic  Melody® Transcatheter  Pulmonary  Valve
Model  PB10)  was  implanted,  according  to  the  technique
reviously  described  [7—13]. Risk  for  coronary  compres-
ion  was  assessed  with  aortic  root  angiogram  in  two  views
lateral  and  four-chamber  views)  and/or  selective  coronary
ngiogram,  prior  to  and  during  high-pressure  balloon  inﬂa-
ion.  Importantly,  we  ensured  that  the  size  of  the  balloon
sed  to  assess  coronary  compression  always  matched  the
xpected  diameter  of  the  bare  metal  stent  or  Melody® valve.
ost  of  the  patients  had  pre-stenting  of  the  RVOT  with  CP
NuMed  Inc.,  Hopkinton,  NY,  USA)  and/or  ev3  LD  Max  (ev3
ndovascular  Inc.,  Plymouth,  MN,  USA)  [14].
ata reporting
ata  collected  for  each  patient  included  their  congenital
ardiac  lesions,  the  substrate  of  RVOT  (conduit,  biopros-
hesis  or  pericardial  patch  reconstruction  of  outﬂow  tract),
he  number  and  type  of  previous  surgeries  and  their  New
ork  Heart  Association  (NYHA)  class.  The  following  pri-
ary  outcomes  were  collected:  procedural  success  (no  or
rivial  regurgitation  on  post-implantation  angiogram  and
6 A.  Fraisse  et  al.
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Table  1  Patient  characteristics.
All  patients
(n =  64)
Age  at  TPVI  (years)  21.4  (10.5—77.3)
Women  38  (59.4)
NYHA  class
I  16  (25.0)
II  39  (60.9)
III  9  (14.1)
Congenital  heart  disease
TOF—PA-VSD 32  (50.0)
Common  arterial  trunk 9  (14.1)
LVOT  disease  post  Ross  surgery  8  (12.5)
DORV  and  variants  6  (9.4)
Transposition  of  the  great  arteries  5  (7.8)
Pulmonary  stenosis  3  (4.7)
cc-TGA  1  (1.6)
Previous  surgeries
1 10  (15.6)
2  24  (37.5)
3  18  (28.1)
4  9  (14.1)
5  3  (4.7)
Primary  indication(s)  number  (%)
Pulmonary  stenosis  and  regurgitation  43  (67.2)
Pulmonary  stenosis  14  (21.9)
Pulmonary  regurgitation  7  (10.9)
Pre-stenting  62  (96.9)
Data are median (range) or number (%). cc-TGA: congenitally
corrected transposition of the great arteries; DORV: double
outlet right ventricle; LVOT: left ventricular outﬂow tract;
NYHA: New York Heart Association; PA-VSD: pulmonary atresia-
ventricular septal defect; TOF: tetralogy of Fallot; TPVI:
transcatheter pulmonary valve implantation.
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 post-implantation  peak-to-peak  gradient  ≤  20  mmHg),
omplications,  TPVI-related  death  and  mid-term  follow-up
uccess.
Patients  were  evaluated  (clinical  assessment,  ECG,  chest
-ray  and  echocardiography)  24  hours  after  implantation,  at
,  3,  6  and  12  months  and  every  year.  Echocardiographic
ata  were  collected:  any  signiﬁcant  (>  trivial)  pulmonary
egurgitation,  systolic  right  ventricular  pressure  (if  tricus-
id  regurgitation),  ventricular  diameters  and  function.  MRI
as  performed  within  6  months  after  TPVI.  Cine-angiogram
ooking  for  stent  fractures  was  performed  at  any  time  during
ollow-up  in  case  of  increased  RVOT  gradient  during  follow-
p,  signs  of  pulmonary  embolism,  appearance  of  or  increase
n  pulmonary  regurgitation,  with  or  without  stent  fractures
n  standard  X-ray.  Stent  fractures  with  no  clinical  reper-
ussion  or  haemodynamic  consequences  were  disregarded.
he  follow-up  information  was  collected  from  the  patient’s
hart.  Any  death  or  reintervention  occurring  during  follow-
p  was  fully  investigated.
tatistical analysis
ASW  statistics  17.0  (SPSS  Inc.,  SPSS,  Chicago,  USA)  was  used
or  statistical  analysis.  Data  are  expressed  as  mean  (stan-
ard  deviation  [SD]  or  range)  if  normally  distributed  or  as
edian  (range).  Nominal  variables  are  expressed  as  numbers
nd  percentages.  Student’s  paired  t  test  was  used  to  eval-
ate  the  difference  after  TPVI.  Categorical  variables  were
ompared  using  the  2 test,  the  Wilcoxon  signed-rank  test
nd  the  Mann—Whitney  U  test.  Kaplan—Meier  actuarial  sur-
ival  curves  were  obtained.  All  tests  were  two-sided  and  a
 value  of  <  0.05  was  considered  statistically  signiﬁcant.
esults
atient characteristics
haracteristics  of  the  64  included  patients  are  reported  in
able  1.  The  majority  (60.9%)  of  the  patients  were  NYHA
lass  II,  while  no  patient  was  class  IV.  Indications  for  valve
mplantation  was  pure  stenosis  in  14  patients  (21.9%),  pure
egurgitation  in  seven  (10.9%)  and  association  of  stenosis  and
egurgitation  in  43  (67.2%).
rocedural data and early results
 femoral  vein  approach  was  used  in  62  cases  (96.9%)
hereas  two  patients  underwent  TPVI  through  jugular
ccess.  The  valve  was  successfully  delivered  in  all  patients.
edian  (range)  procedural  time  was  92.5  (25—250)  min-
tes.  Pre-stenting  was  performed  in  96.9%  of  the  patients
sing  bare  CP  stents  (Numed,  Hopkinton,  NY,  USA),  cov-
red  CP  stents  (Numed,  Hopkinton,  NY,  USA)  or  ev3  LD  Max
ev3  Endovascular  Inc.).  A  maximum  of  four  stents  were
mplanted.  In  three  of  the  seven  patients  with  pure  pul-
onary  regurgitation,  Russian  dolls  and/or  jailing  technique
ere  used  [15].
A  22-mm  Ensemble  delivery  system  was  used  to  implant
he  valve  (Fig.  1)  in  61  patients  (95.3%),  whereas  a  20-mm
ystem  was  used  in  two  patients  (3.1%)  and  an  18-mm  system
n  one  patient  (1.6%).
g
b
rAssociated  procedures  were  performed  in  11  cases
17.2%)  and  included  atrial  septal  defect  closure  (n  =  2),
ortic  coarctation  stenting  (n  =  1),  pulmonary  artery  branch
tenting  (n  =  5),  main  pulmonary  artery  bifurcation  stent-
ng  (n  =  2)  and  right  coronary  artery  dilation  (n  =  1).  In
ll  of  these  patients,  the  pulmonary  valve  was  in  a
table  position.  Mean  right  ventricular  systolic  pressure,
ight  ventricle  to  pulmonary  artery  gradient  and  right
entricle  to  aorta  pressure  ratio  were  all  signiﬁcantly
educed  from  pre  to  post-procedure  (Table  2).  Among
7  patients  with  signiﬁcant  stenosis  (43  patients  with
ixed  lesion  and  14  with  isolated  stenosis),  right  ventric-
lar  systolic  pressure  and  peak-to-peak  systolic  gradient
cross  the  RVOT  reduced  signiﬁcantly  in  51  (89.5%),
ith  <  20  mmHg  gradient  after  the  procedure.  The  other
ix  of  these  patients  (10.5%)  had  a  residual  peak-to-peak
radient  >  20  mmHg,  including  ﬁve  with  a  non-expandable
ioprosthesis.
No  patient  had  mild  or  a  more  severe  form  of  pulmonary
egurgitation  after  TPVI.
Transcatheter  pulmonary  valve  registry  611
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implanted with no residual regurgitation on the control angiogram.
Procedural complications
Minor  complications  occurred  in  11  patients  (17.2%):  a  con-
ﬁned  tear  after  balloon  dilation  of  a  homograft  conduit
(n  =  7),  treated  with  covered  (n  =  4)  or  bare  (n  =  3)  stent
implantation;  minor  bleeding  from  the  oro-tracheal  tube
(n  =  1)  with  spontaneous  resolution;  a  false  aneurysm  of  the
left  femoral  artery  (n  =  1)  with  favourable  outcome  after
local  compression;  blood  transfusion  requirement  (n  =  1)  due
to  signiﬁcant  bleeding  at  the  femoral  access;  and  groin
haematoma  (n  =  1).
Post-TPVI course and outcome
The  median  (range)  hospital  stay  was  3  (2—5)  days,  and
median  follow-up  time  was  4.6  (0.2—5.2)  years.  Three
patients  died.  Firstly,  a  26-year-old  man  with  corrected
tetralogy  of  Fallot-pulmonary  atresia  died  2.6  months  after
TPVI.  He  presented  in  acute  heart  failure  after  a  10-day  his-
tory  of  low-grade  fever.  By  echocardiography,  the  RVOT  was
obstructed  by  valve  vegetation  and  Staphylococcus  epider-
midis  was  obtained  from  blood  culture.  He  was  scheduled
for  surgery  the  day  after  his  admission  but  died  during
the  night  from  ventricular  ﬁbrillation.  Infective  endocarditis
was  conﬁrmed  at  autopsy.  Secondly,  an  18-year-old  woman
with  corrected  tetralogy  of  Fallot-pulmonary  atresia  expe-
rienced  endocarditis  28.3  months  after  TPVI.  She  presented
after  1  week  of  low-grade  fever  in  septic  shock  with  severe
right  ventricular  and  liver  failure.  RVOT  was  obstructed  by
a
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Table  2  Haemodynamic  results.
Pre-pro
(n  =  64)
RV  systolic  pressure  (mmHg)  74  (2
Peak-to-peak  systolic  RV-PA  gradient  (mmHg)  50  (5
RV/aorta  pressure  ratio  0.82  (0
Data are mean (range). PA: pulmonary artery; RV: right ventricle.ng a purely stenotic lesion. B. A 22-mm Melody® valve has been
chocardiography  Doppler  with  121  mmHg  peak  gradient.
urgery  was  planned  in  the  afternoon  of  her  admission.  She
ent  into  ventricular  ﬁbrillation  upon  entering  the  operating
oom.  She  was  rapidly  put  onto  extracorporeal  membrane
xygenation  support.  The  RVOT  conduit  was  extracted,
ut  the  patient  subsequently  died  from  multiorgan  failure
severe  neurological  impairment).  Streptococcus  sanguinis
as  found  on  blood  culture  with  large  obstructive  vege-
ations  on  the  Melody® valve.  Thirdly,  a  57-year-old  man
ith  a  corrected  tetralogy  of  Fallot  died.  He  had  a  severely
epressed  right  ventricular  function  that  did  not  improve
fter  TPVI.  He  died  23.7  months  after  TPVI  from  end-stage
ardiac  failure  while  he  was  considered  for  heart  transplan-
ation.
Surgical  reoperation  was  performed  in  three  patients
ecause  of  resurgence  of  conduit  obstruction  (24  and  29
onths  after  TPVI)  in  two  and  severe  tricuspid  insufﬁciency
n  one.  In  the  last  patient,  the  existing  tricuspid  regurgita-
ion  did  not  improve  after  TPVI.  Surgery  was  performed  30
onths  after  TPVI.  Melody  valve  was  replaced  by  a  homo-
raft  during  the  tricuspid  annuloplasty.
The  only  other  patient  who  experienced  late
omplications  during  follow-up  was  a  21-year-old  woman
ho  suffered  from  infective  endocarditis  4.2  years  after
PVI.  She  had  been  lost  to  follow-up  and  has  discontinued
spirin.  She  experienced  frequent  cystitis  in  the  setting
f  an  associated  urogenital  malformation  and  she  was
ot  compliant  to  bacterial  endocarditis  prophylaxis.  She
resented  with  a  moderately  increased  mean  RVOT  gradient
cedure Post-procedure
(n  =  64)
P
5—130)  42  (20—67)  <  0.001
—115)  14  (0—33)  <  0.001
.19—1.44)  0.41  (0.17—0.72)  <  0.001
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cigure 2. Kaplan—Meier curves showing freedom from death,
eintervention and death and reintervention.
25  mmHg  by  Doppler).  Staphylococcus  haemolyticus  was
ound  in  blood  cultures  and  she  was  treated  medically  with
riple  antibiotherapy.  Her  outcome  was  favourable,  with  a
oderate  residual  RVOT  obstruction  of  30—35  mmHg  (mean
oppler  gradient)  at  last  follow-up.
Freedom  from  death,  reintervention  and
eath/reintervention  is  shown  in  Fig.  2.  No  signiﬁcant
tent  fractures  were  noted  during  follow-up.
RI data
oupled  data  pre-implantation  and  6  months  after  implanta-
ion  were  available  in  43  cases.  By  6-month  post-procedure
RI,  reductions  in  right  ventricular  volumes  and  pulmonary
egurgitation  fractions  had  occurred,  and  these  varied  by
ndication  for  TPVI  (stenosis,  regurgitation  or  mixed  lesion)
Table  3).  Right  ventricular  end-diastolic  volumes  and  pul-
onary  regurgitation  fractions  improved  signiﬁcantly  in
atients  with  mixed  and  regurgitant  lesion  while  the  change
as  much  less  pronounced  in  purely  stenotic  RVOT.  Left  ven-
ricular  volumes  and  biventricular  function  did  not  change
igniﬁcantly  after  TPVI  (Table  3).
iscussion
PVI  is  used  worldwide,  and  recent  studies  have  demon-
trated  very  good  early  and  short-term  results  [8—13].
owever,  medium-  and  long-term  follow-up  is  currently
acking.  With  the  exception  of  an  Italian  registry,  that
eported  a  median  follow-up  of  2.5  years  [13],  the  present
tudy  is  the  only  one  to  provide  mid-term  data,  with  a
edian  follow-up  of  4.6  years.  Although  Lurz  et  al.  [9]
eported  a  median  follow-up  of  2.4  years,  their  study  does
ot  reﬂect  TPVI  in  the  current  era  as  they  included  the  very
rst  cases  of  TPVI  [9].With  a  median  (range)  procedure  duration  of  92.5
25—250)  minutes,  our  implantation  time  compares
avourably  to  other  studies  [8—13].  With  a  100%  successful
mplantation  rate,  our  registry  demonstrates  excellent
b
v
t
MA.  Fraisse  et  al.
rocedural  results.  This  is  comparable  to  the  Italian  registry
hat  reported  a  95.6%  successful  implantation  rate  [13].
ur  procedural  complication  rate  was  low.  Most  were
inor  complications.  There  were  no  cases  of  procedural
ortality  and  no  patients  were  sent  for  surgery.  Conduit
upture  that  occurred  during  balloon  interrogation  for
oronary  compression  was  the  most  frequent  procedural
omplication.  Although  this  occurred  in  almost  11%,  no
oronary  compression  was  misdiagnosed  using  the  diagnostic
odality  followed  in  the  present  registry.  Because  diagnosis
f  coronary  compression  by  pre-procedural  imaging  (e.g.
omputed  tomography  and/or  MRI)  is  not  very  accurate,
ngiography  during  balloon  dilation  was  performed  in
very  patient,  with  aortic  root  angiograms  in  at  least
wo  projections  and/or  a  selective  coronary  angiogram.
mportantly,  we  tend  to  use  a  non-compliant  balloon  that
atches  the  intended  Melody® implant  diameter  and  length
14].
Three  patients  (4.7%)  died  during  the  present  study,
ncluding  two  from  infectious  endocarditis.  In  this  study,
nfective  endocarditis  occurred  in  four  patients  (6.3%),
ncluding  three  cases  that  presented  >  18  months  after  TPVI.
nformation  about  three  of  these  four  patients  has  been  pre-
iously  published  [16]  and  this  problem  has  been  reported  in
ther  studies  [12,13]  as  well  as  in  a small  cohort  of  patients
17]. Late  infective  endocarditis  with  the  Melody® valve
aises  some  important  concerns.  In  the  current  study,  a  50%
ortality  rate  from  infective  endocarditis  was  particularly
igh,  as  was  the  need  for  emergency  surgery.  Of  interest,
spirin  had  been  discontinued  in  three  of  the  four  cases  and
ne  of  them  was  not  compliant  to  bacterial  endocarditis  pro-
hylaxis.  In  a  recent  literature  review,  the  overall  mortality
as  13%  and  over  half  of  the  patients  underwent  surgical
ioprosthesis  explantation  [17]. The  most  common  microor-
anisms  were  Staphylococcus  and  Streptococcus  species
17], as  in  our  study.  Data  from  larger  multicentre  registries
ay  help  to  identify  the  true  incidences  of  explantation  and
eath,  and  possible  risk  factors.  Strict  antibiotic  prophylaxis
nd  extensive  preprocedure  infectious  disease  evaluation
ust  be  done  in  all  patients.  Urgent  intervention  to  relieve
cute  obstruction  is  likely  to  reduce  mortality  and  should
lways  be  considered  along  with  aggressive  management  of
nfective  endocarditis.
The  last  patient  —  who  died  from  progressive  heart
ailure  —  had  TPVI  in  the  setting  of  advanced  heart  fail-
re  with  biventricular  dysfunction.  Clearly,  patients  should
ndergo  surgical  or  TPVI  before  they  become  symptomatic.
ecent  studies  on  repaired  tetralogy  of  Fallot  have  demon-
trated  that  relying  on  symptoms  related  to  heart  failure
s  the  major  criteria  for  surgical  or  TPVI  results  in  patients
eceiving  a  pulmonary  valve  when  their  right  ventricle  is
arkedly  dilated.  In  such  patients,  right  ventricular  size
ill  often  not  return  to  normal  and  patients  will  continue
o  deteriorate.  In  the  present  study,  indication  for  TPVI
as  mainly  considered  in  asymptomatic  patients  with  MRI,
lectrocardiographic  and  haemodynamic  criteria.  Right  and
eft  ventricular  ejection  fractions  did  not  change  signiﬁ-
antly  after  the  procedure  because  TPVI  was  performed
efore  signiﬁcant  ventricular  function  deterioration.  Right
entricular  end-diastolic  volume  and  pulmonary  regurgi-
ation  improved  signiﬁcantly  by  6-month  post-procedure
RI  among  patients  with  regurgitant  or  mixed  lesions.
Transcatheter  pulmonary  valve  registry  613
Table  3  Magnetic  resonance  imaging  data.
Pre-procedure
(n  =  43)
Post-procedure  (6-month  follow-up)
(n  =  43)
P
End-diastolic  RV  volume  (mL/m2)  111.1  ±  39.7  87.3  ±  24.7  0.0002
Mixed  (n  =  27)  114.2  ±  37.4  86.9  ±  21.0  0.0002
Stenosis  (n  =  9)  95.0  ±  35.9  85.0  ±  30.2  0.49
Regurgitation  (n  =  7)  119.3  ±  36.5  92.0  ±  34.5  0.02
RV  ejection  fraction  (%)  48.1  ±  11.2  48.4  ±  13.3  0.6
Mixed  (n  =  27) 49.3  ±  12.3 50.8  ±  15.9 0.8
Stenosis  (n  =  9) 48.6  ±  7.8 49.4  ±  12.4 0.93
Regurgitation  (n  =  7) 40.6 ±  14.6 35.4  ±  15.9 0.48
Pulmonary  regurgitation  fraction  (%) 30.4  ±  16.3 3.5  ±  6.6 0.03
Mixed  (n  =  27)  31.5  ±  12.2  2.9  ±  6.5  0.05
Stenosis  (n  =  9)  10.5  ±  15.0  5.1  ±  8.0  0.3
Regurgitation  (n  =  7) 46.4 ±  24.0  1.4  ±  3.5  0.01
End-systolic  LV  volume  (mL/m2)  78.0  ±  14.1  80.6  ±  24.4  0.59
Mixed  (n  =  27)  77.7  ±  22.1  82.8  ±  22.1  0.75
Stenosis  (n  =  9)  83.1  ±  22.5  79.0  ±  25.2  0.88
Regurgitation  (n  =  7)  71.5  ±  37.8  73.0  ±  34.7  0.6
LV  ejection  fraction  (%)  56.6  ±  2.8  56.4  ±  9.0  0.68
Mixed  (n  =  27)  56.2  ±  9.2  57.7  ±  9.9  0.46
Stenosis  (n  =  9)  59.9  ±  7.9  55.0  ±  10.0  0.82
Regurgitation  (n  =  7)  53.0  ±  11.8  53.0  ±  11.8  0.81
Data are mean ± standard deviation. LV: left ventricle/ventricular; RV: right ventricle/ventricular.
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RConversely,  in  stenotic  RVOT,  ventricular  end-diastolic
volume  and  pulmonary  regurgitation  did  not  change  sig-
niﬁcantly  after  TPVI.  The  lack  of  change  was  due  to
lower  starting  values  rather  than  higher  end  values.  Our
results  are  in  agreement  with  a  recent  study  that  reported
that  the  type  of  right  ventricular  loading  (pressure  ver-
sus  volume)  before  pulmonary  valve  replacement  affects
the  remodelling  pattern  [18].  In  purely  stenotic  RVOT,  a
decrease  in  the  end-diastolic  volume  after  TPVI  was  absent
[18].
No  severe  fractures  with  clinical  or  haemodynamic  conse-
quences  were  reported  in  our  study.  However,  stent  fracture
has  been  reported  with  a  rate  as  high  as  30%  at  6  months
[11],  although  further  studies  have  shown  that  pre-stenting
reduces  this  rate  signiﬁcantly  [12].  The  majority  of  our
patients  were  prestented,  which  could  help  to  explain  our
low  rate.  This  may  also  be  due  to  the  non-systematic  search
of  this  complication.  We  only  counted  signiﬁcant  stent  frac-
tures  (i.e.  those  with  a  clinical  impact  or  haemodynamic
disturbance),  whereas  some  studies  have  included  all  type
of  fractures.  Some  authors  recommend  a  systematic  search
for  stent  fracture  using  high-radiation  dose  imaging  modal-
ities  including  X-ray  and  cine-angiogram  (which  is  a  more
sensitive  tool)  in  all  patients  during  follow-up.  We  per-
formed  cine-angiogram  only  in  patients  with  suspected  stent
fractures  based  on  clinical  and  echographic  parameters.
Resurgence  of  RVOT  obstruction  after  TPVI  in  non-infected
patients  usually  relates  to  stent  fractures  secondary  to  mul-
tiple  stent  fractures  with  loss  of  stent  integrity  and  radial
force.imitations
he  number  of  patients  treated  in  the  current  study  was  not
ery  high  and,  despite  reasonably  long  follow-up,  ideally  this
ould  be  longer,  especially  to  assess  the  frequency  of  late
omplications  such  as  infectious  endocarditis.
onclusions
n  the  current  era,  the  feasibility  of  TPVI  is  excellent
nd  mid-term  follow-up  with  MRI  demonstrates  sustained
mprovement  of  RVOT  function.  However,  late  occurrence
f  endocarditis  is  of  concern.  Longer  follow-up  with  more
atients  treated  is  urgently  needed  to  better  assess  the
ong-term  outcome  of  RVOT  function  after  TPVI.
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